Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.69 |
| ▸ | GSK3B | P49841 | 2/20 | 0.69 |
| ▸ | PIM1 | P11309 | 18/20 | 0.62 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.62 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689480 | 0.86 | PIM1 (0.78) | PIM1PIM2PIM3 | |
| SCHEMBL14688747 | 0.84 | PIM1 (0.64) | GSK3AGSK3BPIM1PIM2PIM3 | |
| SCHEMBL14688550 | 0.82 | PIM1 (0.64) | GSK3AGSK3BPIM1PIM2PIM3 | |
| SCHEMBL5826949 | 0.82 | GSK3A (1.00) | GSK3AGSK3BPIM1PIM2PIM3 | |
| SCHEMBL19960697 | 0.80 | GSK3A (0.64) | GSK3AGSK3BPIM1PIM2PIM3 | |
| SCHEMBL14689155 | 0.78 | PIM1 (0.64) | GSK3AGSK3BPIM1PIM2PIM3 | |
| SCHEMBL14689212 | 0.77 | PIM1 (1.00) | GSK3AGSK3BPIM1PIM2PIM3 | |
| SCHEMBL14688811 | 0.77 | PIM1 (0.64) | GSK3AGSK3BPIM1PIM2PIM3 | |
| SCHEMBL14688897 | 0.77 | PIM1 (1.00) | PIM1PIM2PIM3 | |
| SCHEMBL14688974 | 0.76 | PIM1 (0.77) | PIM1PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | GSK3A 2239/4885GSK3B 2319/4885PIM1 2202/4885 |
| US-20180072720-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | GSK3A 2239/4885GSK3B 2319/4885PIM1 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.